The Unique Demands of Injectable Formulations Injectabl […]
Injectable drug products ? administered intravenously, intramuscularly, or subcutaneously ? bypass the body’s natural barriers and enter the bloodstream directly. This route of administration demands an absolute standard of quality that few other pharmaceutical processes match: sterility, absence of pyrogens, precise particle size control below 5 ?m (to prevent capillary embolism), and formulation stability that holds through terminal sterilization and long-term storage.
High pressure homogenization is a core enabling technology for several critical injectable product categories: intravenous fat emulsions (IVFE) for total parenteral nutrition, liposomal injectables for cancer therapy, propofol and other anesthetic emulsions, and nanoparticle drug delivery systems. In each case, the homogenizer must not only achieve the target particle size but do so within an aseptic or sterile processing environment that meets cGMP requirements.
| Product Type | Pressure (bar) | Passes | Target Droplet Size | Regulatory Context |
|---|---|---|---|---|
| IV Fat Emulsion (Intralipid-type) | 600-1000 | 3-8 | 200-500 nm | USP Globule Size Limits |
| Propofol Injectable Emulsion | 800-1200 | 5-10 | 150-300 nm | FDA/EMA sterile product requirements |
| Liposomal Doxorubicin (Doxil-type) | 600-1000 | 5-8 | 80-120 nm | Liposome drug product guidance |
| Paclitaxel Albumin Nanoparticles | 1000-1500 | 8-12 | 100-200 nm | NDA/ANDA nanoparticle characterization |
| mRNA-LNP (COVID Vaccine-type) | 800-1200 | 4-8 | 60-100 nm | USP / Ph. Eur. 2.9.19 |
| Diagnostic Imaging Emulsion | 600-1000 | 3-6 | 200-400 nm | Perfluorocarbon emulsion specs |
Intravenous fat emulsions (e.g., Intralipid, ClinOleic, SMOFlipid) provide essential fatty acids and calories to patients who cannot eat. These are oil-in-water emulsions ? typically 10-30% soybean oil, MCT, olive oil, or fish oil dispersed in water with egg lecithin as emulsifier.
The USP monograph sets rigorous globule size requirements that make HPH indispensable:
These limits exist because fat globules larger than 5 ?m can lodge in pulmonary capillaries and cause fat embolism syndrome ? a potentially fatal complication. Achieving PFAT5 below 0.05% requires multiple high-pressure passes. A typical manufacturing process runs 5-8 passes at 800-1000 bar, with the PFAT5 value declining with each pass:
Smallnm pharmaceutical homogenizers are designed for this exact multi-pass workflow, with automated pass counting, pressure logging, and batch records that support regulatory submissions.
For injectable products that cannot be terminally sterilized by autoclaving (because the emulsion would break down at 121?C), aseptic processing is required. The homogenizer becomes part of the sterile boundary, and every component that contacts product must be sterilizable:
A key advantage of high pressure homogenization for injectables is the predictability of scale-up. Because homogenization is a continuous, well-characterized process driven by pressure and number of passes (rather than batch-dependent mixing), results from a Smallnm 5-10 L/h lab unit translate directly to a 1000 L/h production unit:
The critical scale-up parameter is energy density ? the total mechanical energy delivered to each unit volume of product. As long as the pressure and number of passes are held constant, the droplet size distribution remains consistent across all scales. This eliminates the costly trial-and-error typically associated with scaling up other emulsification technologies.
No ? homogenization reduces particle size to 100-500 nm but does not sterilize. A 0.22 ?m sterilizing-grade filter must follow homogenization. However, HPH significantly improves filterability by eliminating large droplets that would prematurely clog the filter membrane.
We provide IQ/OQ documentation packages including materials of construction certificates (316L/316L ESR), surface finish measurement reports (Ra values), pressure calibration certificates, SIP temperature mapping data, and factory acceptance test (FAT) reports. PQ protocols are developed collaboratively with your validation team.
Smallnm pharma homogenizers use ceramic (zirconia) or tungsten carbide valve components at the high-wear points rather than metal-on-metal contact. Product-contact surfaces are electropolished 316L. The sterile filtration step downstream of the homogenizer provides an additional particulate barrier. Routine extractables and leachables studies can be supported with component material data.
With optimized hold-up volume design, yield loss is typically 2-5% of batch volume. Smallnm pharma homogenizers minimize hold-up through sloped product paths, bottom-outlet vessel connections, and low-dead-volume valve designs. For high-value APIs (e.g., liposomal doxorubicin, where API cost can exceed $10,000/g), we offer custom low-hold-up configurations that reduce loss to under 1%.
Yes. HPH is the established manufacturing technology for IV fat emulsions, propofol, and several liposomal drugs with approved NDAs and ANDAs. The FDA’s Guidance for Industry on Liposome Drug Products (2018) and USP explicitly reference high pressure homogenization as the standard method for globule size control in injectable emulsions.
Smallnm pharmaceutical homogenizers are installed in cGMP facilities manufacturing parenteral nutrition, anesthetic emulsions, and liposomal drugs. Our equipment supports your regulatory pathway with comprehensive validation documentation and application support from our pharmaceutical engineering team.
Contact our pharma applications team to schedule a technical discussion and equipment demonstration.
Written by
Rethinking Pigment Dispersion: HPH vs Bead Mills The co […]
Liquid Phase Exfoliation: The Scalable Route to 2D Nano […]
Why Emulsions for Eye Drops? The ocular surface present […]